Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?

Transplant Proc. 1991 Feb;23(1 Pt 2):1106-7.

Authors

S M Cockfield¹, J Preiksaitis, E Harvey, C Jones, D Hebert, P Keown, P F Halloran

Affiliation

¹ Department of Medicine, University of Alberta, Edmonton, Canada.

PMID: 1846454

No abstract available

MeSH terms

Age Factors
Antibodies, Monoclonal / administration & dosage*
Antilymphocyte Serum / administration & dosage*
Female
Herpesvirus 4, Human
Humans
Immunization Schedule
Immunosuppression Therapy / methods*
Kidney Transplantation / methods*
Lymphoproliferative Disorders / etiology*
Male
Muromonab-CD3
Retrospective Studies
Risk Factors
Sex Factors
Tumor Virus Infections / complications

Substances

Antibodies, Monoclonal
Antilymphocyte Serum
Muromonab-CD3